Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging
Xenograft tumor models are widely studied in cancer research. Our aim was to establish and apply a model for aggressive CD20-positive B-cell non-Hodgkin lymphomas, enabling us to monitor tumor growth and shrinkage in a noninvasive manner. By stably transfecting a luciferase expression vector, we cre...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2015-07-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2015.00010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561840721592320 |
|---|---|
| author | Margarethe Köberle Kristin Müller Manja Kamprad Friedemann Horn Markus Scholz |
| author_facet | Margarethe Köberle Kristin Müller Manja Kamprad Friedemann Horn Markus Scholz |
| author_sort | Margarethe Köberle |
| collection | DOAJ |
| description | Xenograft tumor models are widely studied in cancer research. Our aim was to establish and apply a model for aggressive CD20-positive B-cell non-Hodgkin lymphomas, enabling us to monitor tumor growth and shrinkage in a noninvasive manner. By stably transfecting a luciferase expression vector, we created two bioluminescent human non-Hodgkin lymphoma cell lines, Jeko1(luci) and OCI-Ly3(luci), that are CD20 positive, a prerequisite to studying rituximab, a chimeric anti-CD20 antibody. To investigate the therapy response in vivo, we established a disseminated xenograft tumor model injecting these cell lines in NOD/SCID mice. We observed a close correlation of bioluminescence intensity and tumor burden, allowing us to monitor therapy response in the living animal. Cyclophosphamide reduced tumor burden in mice injected with either cell line in a dose-dependent manner. Rituximab alone was effective in OCI-Ly3(luci)-injected mice and acted additively in combination with cyclophosphamide. In contrast, it improved the therapeutic outcome of Jeko1(luci)-injected mice only in combination with cyclophosphamide. We conclude that well-established bioluminescence imaging is a valuable tool in disseminated xenograft tumor models. Our model can be translated to other cell lines and used to examine new therapeutic agents and schedules. |
| format | Article |
| id | doaj-art-241ba47e871c4a50886fd062db0ea19a |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2015-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-241ba47e871c4a50886fd062db0ea19a2025-01-03T01:23:08ZengSAGE PublishingMolecular Imaging1536-01212015-07-011410.2310/7290.2015.0001010.2310_7290.2015.00010Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence ImagingMargarethe KöberleKristin MüllerManja KampradFriedemann HornMarkus ScholzXenograft tumor models are widely studied in cancer research. Our aim was to establish and apply a model for aggressive CD20-positive B-cell non-Hodgkin lymphomas, enabling us to monitor tumor growth and shrinkage in a noninvasive manner. By stably transfecting a luciferase expression vector, we created two bioluminescent human non-Hodgkin lymphoma cell lines, Jeko1(luci) and OCI-Ly3(luci), that are CD20 positive, a prerequisite to studying rituximab, a chimeric anti-CD20 antibody. To investigate the therapy response in vivo, we established a disseminated xenograft tumor model injecting these cell lines in NOD/SCID mice. We observed a close correlation of bioluminescence intensity and tumor burden, allowing us to monitor therapy response in the living animal. Cyclophosphamide reduced tumor burden in mice injected with either cell line in a dose-dependent manner. Rituximab alone was effective in OCI-Ly3(luci)-injected mice and acted additively in combination with cyclophosphamide. In contrast, it improved the therapeutic outcome of Jeko1(luci)-injected mice only in combination with cyclophosphamide. We conclude that well-established bioluminescence imaging is a valuable tool in disseminated xenograft tumor models. Our model can be translated to other cell lines and used to examine new therapeutic agents and schedules.https://doi.org/10.2310/7290.2015.00010 |
| spellingShingle | Margarethe Köberle Kristin Müller Manja Kamprad Friedemann Horn Markus Scholz Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging Molecular Imaging |
| title | Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging |
| title_full | Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging |
| title_fullStr | Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging |
| title_full_unstemmed | Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging |
| title_short | Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging |
| title_sort | monitoring disease progression and therapeutic response in a disseminated tumor model for non hodgkin lymphoma by bioluminescence imaging |
| url | https://doi.org/10.2310/7290.2015.00010 |
| work_keys_str_mv | AT margarethekoberle monitoringdiseaseprogressionandtherapeuticresponseinadisseminatedtumormodelfornonhodgkinlymphomabybioluminescenceimaging AT kristinmuller monitoringdiseaseprogressionandtherapeuticresponseinadisseminatedtumormodelfornonhodgkinlymphomabybioluminescenceimaging AT manjakamprad monitoringdiseaseprogressionandtherapeuticresponseinadisseminatedtumormodelfornonhodgkinlymphomabybioluminescenceimaging AT friedemannhorn monitoringdiseaseprogressionandtherapeuticresponseinadisseminatedtumormodelfornonhodgkinlymphomabybioluminescenceimaging AT markusscholz monitoringdiseaseprogressionandtherapeuticresponseinadisseminatedtumormodelfornonhodgkinlymphomabybioluminescenceimaging |